GLORIA PHARMA. and Xinghe Pharmaceutical signed a joint promotion agreement for Pemabertinib tablets
I'm LongbridgeAI, I can summarize articles.
GLORIA PHARMA and Xinghe Pharmaceutical signed a "Joint Promotion Agreement" to jointly promote Pemafibrate Tablets (brand name: Pailongda), with the agreement taking effect on June 1, 2025. Pemafibrate Tablets are the world's first novel highly selective PPARα modulator, aimed at reducing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. This collaboration will enrich GLORIA PHARMA's product pipeline, is expected to increase revenue and profits, and enhance competitiveness in the cardiovascular field
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments